Sign inJoin waitlistJoin the waitlist

John Sfakianos

PROFESSOR | Urology · Icahn School of Medicine at Mount Sinai

Credentials: · · ·

History

Icahn School of Medicine at Mount Sinai
Present

Urology
SUNY Downstate Health Sciences University
2008–2013
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
2003–2007

Research

Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study
Proceedings of the National Academy of Sciences of the United States of America · 2019 · 572 citations
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma
Cancer Discovery · 2014 · 525 citations
The effect of age and gender on bladder cancer: a critical review of the literature
Review · BJU international · 2010 · 262 citations

Reza Mehrazin
75 papers
Matthew Galsky
55 papers
Peter Wiklund
49 papers
Ketan Badani
36 papers
Nikhil Waingankar
27 papers · 4 as a fellow
RD
Reuben Ben David
27 papers · 27 as a resident
Kyrollis Attalla
26 papers · 7 as a resident
Alberto Martini
19 papers · 19 as a resident
BB
Bernard Bochner
19 papers
Daniel Ranti
18 papers · 12 as a resident
JR
Jordan Rich
17 papers · 6 as a resident
WO
William Oh
16 papers

Grants

Multi-Scale Analysis of Bacillus Calmette-Guérin (BCG) Resistant Tumor Micro-Environment in Non-Muscle Invasive Bladder Cancer to Identify Novel Therapeutic Axis
National Cancer Institute · R01
PI · $1.4M · Icahn School of Medicine at Mount Sinai
2025–2030
HLA-E and NKG2A Define a Novel Immune Checkpoint Axis in Non-Muscle-Invasive Bladder Cancer
National Cancer Institute · R01
PI · $2.7M · Icahn School of Medicine at Mount Sinai
2023–2028
Identifying Novel Resistance Mechanisms in Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin (BCG)
National Cancer Institute · R21
Contact PI · $424.7K · Icahn School of Medicine at Mount Sinai
2023–2025

Clinical trials

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Principal investigator · Recruiting · Phase 2
John Sfakianos
2025–2032
Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion
Principal investigator · Recruiting
Icahn School of Medicine at Mount Sinai
2024–2026
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
Site PI · Not yet recruiting · Phase 1
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
2026–2029